Shuya Kandori
Overview
Explore the profile of Shuya Kandori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suzuki S, Nagumo Y, Kojo K, Kandori S, Sakurai H, Takahashi R, et al.
BMC Cancer
. 2025 Mar;
25(1):464.
PMID: 40082801
Background: To clarify the long-term prognoses of elderly upper tract urothelial carcinoma (UTUC) patients after surgery. Methods: We used a hospital-based cancer registry data in Japan to extract patients with...
2.
Tanaka T, Kojo K, Suetomi T, Nagumo Y, Midorikawa H, Matsuda T, et al.
Nutrients
. 2025 Mar;
17(5).
PMID: 40077734
: Modern societal stressors have been linked to declining testosterone levels among young men, contributing to somatic, psychological, and sexual health problems. Despite growing evidence suggesting a link between trace...
3.
Kikuchi H, Osawa T, Matsushita Y, Kojima T, Sazuka T, Hatakeyama S, et al.
Jpn J Clin Oncol
. 2025 Feb;
PMID: 39893579
Objective: To validate multiple prognostic models in metastatic renal cell carcinoma patients who received second-line axitinib following first-line nivolumab plus ipilimumab therapy. Methods: Five prognostic models (ACL, albumin, C-reactive protein,...
4.
Kawahara T, Kandori S, Kojima T, Mathis B, Shiga M, Nishiyama H
BMC Res Notes
. 2025 Jan;
18(1):47.
PMID: 39891237
Objective: Recent preclinical and retrospective clinical evidence shows that androgen receptor (AR)-mediated signals have significant roles in development of non-muscle invasive bladder cancer (NMIBC). Here, we conducted a single-center, phase...
5.
Kandori S, Suzuki S, Kojo K, Isoda B, Tanaka T, Nitta S, et al.
BMC Cancer
. 2025 Jan;
25(1):138.
PMID: 39849400
Background: To identify the prognosis of Japanese patients with collecting duct carcinoma (CDC). Methods: We used a hospital-based cancer registry data in Japan to extract CDC cases that were diagnosed...
6.
Shiga M, Nagumo Y, Kojo K, Kandori S, Takahashi R, Isoda B, et al.
Int J Urol
. 2025 Jan;
PMID: 39749844
Objective: Our study assessed the correlation between discrepancies in clinical and pathological T stages and overall survival (OS) in patients with upper urinary tract urothelial carcinoma (UTUC), including renal pelvis...
7.
Kojo K, Oguri T, Tanaka T, Ikeda A, Shimizu T, Fujimoto S, et al.
J Clin Lab Anal
. 2024 Dec;
39(2):e25140.
PMID: 39716823
Background: Inductively coupled plasma mass spectrometry (ICP-MS) is widely used for the accurate measurement of minerals. However, its application to serum essential mineral measurement has not been fully evaluated. The...
8.
Suzuki S, Nagumo Y, Kojo K, Ikeda A, Isoda B, Yamaguchi A, et al.
Photodiagnosis Photodyn Ther
. 2024 Dec;
51:104429.
PMID: 39638220
Background: To investigate variations in diagnostic performance of photodynamic diagnosis (PDD) according to surgical experience. Methods: Data were extracted from patients having pT1 or lower primary tumors that underwent PDD-assisted...
9.
Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, et al.
Cancer Sci
. 2024 Nov;
116(2):444-452.
PMID: 39550694
Nivolumab plus ipilimumab (NIVO+IPI) has a long-term response rate of 30% for patients with metastatic renal cell carcinoma (mRCC). However, 20% of patients develop primary resistant disease (PRD) to NIVO+IPI...
10.
Hamada K, Nagumo Y, Kandori S, Isoda B, Suzuki S, Sano K, et al.
Cancer Sci
. 2024 Nov;
116(2):381-392.
PMID: 39528232
The tumor microenvironment (TME) modulates therapeutic response and prognosis in patients with bladder cancer (BC). The roles of two phospholipase D (PLD) isoforms, PLD1 and PLD2 (hydrolysis of phosphatidylcholine to...